These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 26374679)

  • 1. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pursuit of truly independent data monitoring committees in research.
    Marston L; McKenzie DR; Freemantle N
    BMJ; 2016 May; 353():i2309. PubMed ID: 27172924
    [No Abstract]   [Full Text] [Related]  

  • 3. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.
    Lantos JD; Wendler D; Septimus E; Wahba S; Madigan R; Bliss G
    Clin Trials; 2015 Oct; 12(5):485-93. PubMed ID: 26374686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the ethical and regulatory issues in pragmatic clinical trials.
    Califf RM; Sugarman J
    Clin Trials; 2015 Oct; 12(5):436-41. PubMed ID: 26374676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
    Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
    Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major trial needs three statisticians: why, how and who?
    Pocock SJ
    Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical responsibilities toward indirect and collateral participants in pragmatic clinical trials.
    Smalley JB; Merritt MW; Al-Khatib SM; McCall D; Staman KL; Stepnowsky C
    Clin Trials; 2015 Oct; 12(5):476-84. PubMed ID: 26374687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
    Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
    Trials; 2016 Jan; 17():32. PubMed ID: 26772801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.